← Back to Screener
CollPlant Biotechnologies Ltd Ordinary Shares (CLGN)
Price$0.37
Value ScoreA
Growth ScoreD
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-90.97%
Price vs S&P 500 (4W)-7.75%
VGM Score42.94
Market Capitalization$5.35M
All Metrics
Book Value / Share (Quarterly)$0.47
P/TBV (Annual)3.09x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)99.19%
Cash Flow / Share (Quarterly)$-0.74
Price vs S&P 500 (YTD)-81.66%
Gross Margin (TTM)64.78%
Net Profit Margin (TTM)-484.56%
EPS (TTM)$-0.93
10-Day Avg Trading Volume0.06M
EPS Excl Extra (TTM)$-0.93
Revenue Growth (5Y)-17.33%
EPS (Annual)$-0.94
ROI (Annual)-123.35%
Gross Margin (Annual)70.39%
Net Profit Margin (5Y Avg)-1883.09%
Cash / Share (Quarterly)$0.44
Revenue Growth QoQ (YoY)-63.41%
ROA (Last FY)-88.77%
Revenue Growth TTM (YoY)360.39%
EBITD / Share (TTM)$-0.87
ROE (5Y Avg)-65.77%
Operating Margin (TTM)-484.31%
Cash Flow / Share (Annual)$-1.27
P/B Ratio0.88x
P/B Ratio (Quarterly)2.93x
Net Income / Employee (Annual)$-294,600
EV / Revenue (TTM)-0.10x
Net Interest Coverage (TTM)-40.21x
ROA (TTM)-77.21%
EPS Incl Extra (Annual)$-0.94
Current Ratio (Annual)4.44x
Quick Ratio (Quarterly)2.31x
3-Month Avg Trading Volume0.10M
52-Week Price Return-81.90%
Revenue / Employee (TTM)$60,800
Tangible BV / Share (Quarterly)$0.47
P/S Ratio (Annual)2.26x
Asset Turnover (Annual)0.03x
52-Week High$3.23
Operating Margin (5Y Avg)-1920.42%
EPS Excl Extra (Annual)$-0.94
CapEx CAGR (5Y)-44.25%
26-Week Price Return-83.04%
Quick Ratio (Annual)4.29x
13-Week Price Return-41.55%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.53x
Enterprise Value$-243,000
Revenue / Share Growth (5Y)-26.26%
Asset Turnover (TTM)0.16x
Book Value / Share Growth (5Y)10.26%
Revenue / Employee (Annual)$60,800
Inventory Turnover (Annual)2.32x
Pretax Margin (Annual)-484.56%
Cash / Share (Annual)$1.04
3-Month Return Std Dev104.58%
Gross Margin (5Y Avg)31.26%
Net Income / Employee (TTM)$-294,600
ROE (Last FY)-123.35%
Net Interest Coverage (Annual)-28.00x
EPS Basic Excl Extra (Annual)$-0.94
Receivables Turnover (TTM)31.40x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.93
Receivables Turnover (Annual)6.87x
ROI (TTM)-114.07%
P/S Ratio (TTM)2.26x
Pretax Margin (5Y Avg)-1883.09%
Revenue / Share (Annual)$0.19
Tangible BV / Share (Annual)$1.16
Price vs S&P 500 (52W)-106.27%
Year-to-Date Return-73.50%
5-Day Price Return-7.48%
EPS Normalized (Annual)$-0.94
ROA (5Y Avg)-41.38%
Net Profit Margin (Annual)-484.56%
Month-to-Date Return-7.71%
Cash Flow / Share (TTM)$-0.50
EBITD / Share (Annual)$-0.87
Operating Margin (Annual)-484.31%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-65.77%
EPS Basic Excl Extra (TTM)$-0.93
P/TBV (Quarterly)2.96x
P/B Ratio (Annual)3.06x
Inventory Turnover (TTM)1.65x
Pretax Margin (TTM)-484.56%
Book Value / Share (Annual)$1.18
Price vs S&P 500 (13W)-49.80%
Beta0.69x
P/FCF (Annual)5.88x
Revenue / Share (TTM)$0.19
ROE (TTM)-114.07%
52-Week Low$0.27
vGradeA
gGradeD
mGradeF
vgmGradeC
Show chart for
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.00
4.00
4.14
4.14
Industry Peers — Orthopedic & Prosthetic Devices(33)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CLGNCollPlant Biotechnologies Ltd Ordinary Shares | A | D | F | $0.37 |
| ISRGIntuitive Surgical Inc. | F | B | C | $422.06 |
| EWEdwards Lifesciences Corp | D | C | C | $85.96 |
| STESTERIS plc | C | B | C | $212.35 |
| ZBHZimmer Biomet Holdings, Inc. | B | C | C | $87.33 |
| ALGNAlign Technology Inc | B | C | C | $167.74 |
| SNNSmith & Nephew plc | B | C | C | $30.61 |
| MSAMine Safety Incorporated | B | C | C | $161.30 |
| ESTAEstablishment Labs Holdings Inc. | F | A | B | $74.31 |
| ENOVEnovis Corporation | B | D | C | $23.78 |
| CDRECadre Holdings, Inc. | C | C | D | $30.01 |
About
CollPlant Biotechnologies develops regenerative and aesthetic medicine solutions using its proprietary plant-based rhCollagen technology for 3D bioprinting and tissue engineering applications. The company generates revenue through BioInk product sales, rhCollagen therapeutics for aesthetics and medical indications, and strategic partnerships. Its primary markets span the United States, Europe, Canada, and Israel, targeting opportunities in tissue repair, organ manufacturing, and medical aesthetics.